I-wei L. Ho

Taipei, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".

Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: May 10, 2026

Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort".

Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort".

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: May 03, 2026

Multi-agent chemotherapy for refractory head and neck cancer.

Multi-agent chemotherapy for refractory head and neck cancer.

Journal: Journal of the Chinese Medical Association : JCMA

Published: January 08, 2026

SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).

SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 18, 2025

Platinum and 5-FU Salvage Therapy for Severe Liver Crisis in Metastatic Breast Cancer: Efficacy and Analysis of Prognostic Factors.

Platinum and 5-FU Salvage Therapy for Severe Liver Crisis in Metastatic Breast Cancer: Efficacy and Analysis of Prognostic Factors.

Journal: Cancer research and treatment

Published: November 18, 2025

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study.

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study.

Journal: Cancer medicine

Published: September 02, 2025

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort.

Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: June 08, 2025

A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors.

A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors.

Journal: Investigational new drugs

Published: March 17, 2025

Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.

Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial.

Journal: Cancer medicine

Published: January 21, 2025

Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer.

Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast Cancer.

Journal: Journal of Cancer

Published: October 14, 2024

Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma.

Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinoma.

Journal: The oncologist

Published: September 24, 2024

Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.

Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.

Journal: Thoracic cancer

Published: September 21, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026